Isoray, Inc. (NYSE:ISR) Expected to Announce Quarterly Sales of $3.15 Million

Equities research analysts forecast that Isoray, Inc. (NYSE:ISRGet Rating) will post sales of $3.15 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Isoray’s earnings, with the lowest sales estimate coming in at $2.90 million and the highest estimate coming in at $3.43 million. Isoray reported sales of $2.60 million in the same quarter last year, which indicates a positive year-over-year growth rate of 21.2%. The business is scheduled to issue its next earnings report on Monday, January 1st.

On average, analysts expect that Isoray will report full year sales of $12.37 million for the current year, with estimates ranging from $11.40 million to $13.74 million. For the next financial year, analysts anticipate that the firm will post sales of $16.52 million, with estimates ranging from $13.60 million to $19.05 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Isoray.

Separately, initiated coverage on Isoray in a research note on Monday. They set a “sell” rating for the company.

ISR opened at $0.34 on Friday. The company has a market cap of $48.25 million, a P/E ratio of -6.79 and a beta of 0.98. The business’s 50-day moving average is $0.35. Isoray has a 52-week low of $0.31 and a 52-week high of $1.03.

Isoray Company Profile (Get Rating)

IsoRay, Inc is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors.

Further Reading

Get a free copy of the Zacks research report on Isoray (ISR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with's FREE daily email newsletter.